FMR LLC & Abigail Johnson Maintain 10.985% Stake in Beam Therapeutics
Ticker: BEAM · Form: SC 13G/A · Filed: Feb 9, 2024
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, amendment, biotech, investor-confidence
TL;DR
**FMR LLC and Abigail Johnson still own over 10% of Beam Therapeutics, showing strong conviction.**
AI Summary
FMR LLC, a major investment firm, and its Chair and CEO, Abigail P. Johnson, have updated their ownership stake in Beam Therapeutics Inc. As of February 9, 2024, they collectively beneficially own 8,953,800 shares of common stock, representing 10.985% of the company. This filing indicates a significant, continued interest from a large institutional investor, which can signal confidence in Beam Therapeutics' future prospects.
Why It Matters
This filing shows that a major institutional investor, FMR LLC, and its top executive, Abigail P. Johnson, continue to hold a substantial stake in Beam Therapeutics, which can be a positive signal for current and potential investors.
Risk Assessment
Risk Level: low — This filing indicates a stable, significant institutional ownership, which generally reduces volatility and provides a level of confidence.
Analyst Insight
A smart investor would view this as a positive signal, indicating continued institutional confidence in Beam Therapeutics. It might warrant further research into the company's fundamentals and recent performance.
Key Numbers
- 8,953,800 — Shares Beneficially Owned (Total common stock shares owned by FMR LLC and Abigail P. Johnson in Beam Therapeutics Inc.)
- 10.985% — Percent of Class (The percentage of Beam Therapeutics Inc.'s common stock beneficially owned by FMR LLC and Abigail P. Johnson.)
- 07373V105 — CUSIP Number (Unique identifier for Beam Therapeutics Inc. common stock.)
Key Players & Entities
- FMR LLC (company) — reporting person and major investment firm
- Abigail P. Johnson (person) — reporting person, likely Chair and CEO of FMR LLC
- Beam Therapeutics Inc. (company) — the issuer of the common stock
- Delaware (company) — state of incorporation for FMR LLC
- United States of America (person) — citizenship of Abigail P. Johnson
Forward-Looking Statements
- FMR LLC will likely maintain a significant ownership stake in Beam Therapeutics Inc. for the foreseeable future. (FMR LLC) — high confidence, target: 2025-02-09
- The continued substantial ownership by FMR LLC could attract other institutional investors to Beam Therapeutics Inc. (Beam Therapeutics Inc.) — medium confidence, target: 2024-08-09
FAQ
Who are the reporting persons in this SC 13G/A filing?
The reporting persons are FMR LLC and Abigail P. Johnson, as stated in Item 1 of the filing for each reporting person.
What is the total number of shares of Beam Therapeutics Inc. common stock beneficially owned by FMR LLC and Abigail P. Johnson?
Both FMR LLC and Abigail P. Johnson beneficially own 8,953,800 shares of Beam Therapeutics Inc. common stock, as indicated in Item 7 on their respective cover pages and Item 4(a) for FMR LLC.
What percentage of Beam Therapeutics Inc.'s common stock do the reporting persons collectively own?
The reporting persons collectively own 10.985% of Beam Therapeutics Inc.'s common stock, as shown in Item 11 on their respective cover pages and Item 4(b) for FMR LLC.
What is the address of Beam Therapeutics Inc.'s principal executive offices?
Beam Therapeutics Inc.'s principal executive offices are located at 26 Landsdowne Street, Cambridge, MA 02139 USA, as stated in Item 1(b).
Under which rule is this Schedule 13G filed?
This Schedule 13G is filed under Rule 13d-1(c), as indicated by the checked box on the first page of the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 by Abigail P. Johnson regarding Beam Therapeutics Inc. (BEAM).